High-Throughput Screening and Proteomic Characterization of Compounds Targeting Myeloid-Derived Suppressor Cells

[1]  Wei Lu,et al.  Targeting ACYP1-mediated glycolysis reverses lenvatinib resistance and restricts hepatocellular carcinoma progression. , 2023, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[2]  Xiuzhen Chen,et al.  Solvent‐induced proteome profiling for proteomic quantitation and target discovery of small molecular drugs , 2023, Proteomics.

[3]  Z. Yao,et al.  ACYP1 Is a Pancancer Prognostic Indicator and Affects the Immune Microenvironment in LIHC , 2022, Frontiers in Oncology.

[4]  Aubry K. Miller,et al.  Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target , 2022, Nature Chemical Biology.

[5]  Xin Lu,et al.  Enhancing immune checkpoint blockade therapy of genitourinary malignancies by co-targeting PMN-MDSCs. , 2022, Biochimica et biophysica acta. Reviews on cancer.

[6]  X. Wan,et al.  Regulating Histone Deacetylase Signaling Pathways of Myeloid-Derived Suppressor Cells Enhanced T Cell-Based Immunotherapy , 2022, Frontiers in Immunology.

[7]  Yantong Lu,et al.  Targeting Myeloid-Derived Suppressor Cells to Enhance the Antitumor Efficacy of Immune Checkpoint Blockade Therapy , 2021, Frontiers in Immunology.

[8]  P. Paci,et al.  Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma , 2021, Journal of Hematology & Oncology.

[9]  Wenxin Wang,et al.  Regulatory Effects of Histone Deacetylase Inhibitors on Myeloid-Derived Suppressor Cells , 2021, Frontiers in Immunology.

[10]  G. Friedlander,et al.  CD74 is a regulator of hematopoietic stem cell maintenance , 2021, PLoS biology.

[11]  J. Tavernier,et al.  Interleukin-1 as Innate Mediator of T Cell Immunity , 2021, Frontiers in Immunology.

[12]  T. Fukumoto,et al.  Selective targeting of different populations of myeloid-derived suppressor cells by histone deacetylase inhibitors , 2020, Cancer Immunology, Immunotherapy.

[13]  C. Zahnow,et al.  Epigenetic therapy inhibits metastases by disrupting premetastatic niches , 2020, Nature.

[14]  Bernhard Hemmer,et al.  Robust, reproducible and quantitative analysis of thousands of proteomes by micro-flow LC–MS/MS , 2020, Nature Communications.

[15]  M. Ahluwalia,et al.  Glioblastoma Myeloid-Derived Suppressor Cell Subsets Express Differential Macrophage Migration Inhibitory Factor Receptor Profiles That Can Be Targeted to Reduce Immune Suppression , 2019, bioRxiv.

[16]  Mario Leutert,et al.  R2‐P2 rapid‐robotic phosphoproteomics enables multidimensional cell signaling studies , 2019, Molecular systems biology.

[17]  A. Obenauf,et al.  Allies or Enemies—The Multifaceted Role of Myeloid Cells in the Tumor Microenvironment , 2019, Front. Immunol..

[18]  A. Zhitkovich.  N-Acetylcysteine: Antioxidant, Aldehyde Scavenger, and More. , 2019, Chemical research in toxicology.

[19]  S. Carr,et al.  TMT Labeling for the Masses: A Robust and Cost-efficient, In-solution Labeling Approach* , 2019, Molecular & Cellular Proteomics.

[20]  J. Santibañez,et al.  How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions , 2019, Cancer Immunology, Immunotherapy.

[21]  J. Pollard,et al.  Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates , 2019, Cancer Immunology, Immunotherapy.

[22]  J. Utikal,et al.  Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression , 2018, British Journal of Cancer.

[23]  Martin Eisenacher,et al.  The PRIDE database and related tools and resources in 2019: improving support for quantification data , 2018, Nucleic Acids Res..

[24]  Christopher S. Hughes,et al.  Single-pot, solid-phase-enhanced sample preparation for proteomics experiments , 2018, Nature Protocols.

[25]  Kang-Yun Lee,et al.  Correction: S100A9+ MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: the role of RELB , 2018, Oncotarget.

[26]  L. Travassos,et al.  Blockade of MIF–CD74 Signalling on Macrophages and Dendritic Cells Restores the Antitumour Immune Response Against Metastatic Melanoma , 2018, Front. Immunol..

[27]  P. Lowenstein,et al.  Melanoma induced immunosuppression is mediated by hematopoietic dysregulation , 2018, Oncoimmunology.

[28]  M. Zöller.  Janus-Faced Myeloid-Derived Suppressor Cell Exosomes for the Good and the Bad in Cancer and Autoimmune Disease , 2018, Front. Immunol..

[29]  D. Gabrilovich,et al.  Myeloid-derived suppressor cells coming of age , 2018, Nature Immunology.

[30]  G. Lesinski,et al.  Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer , 2018, Journal of clinical pharmacology.

[31]  Bin Zhang,et al.  CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non-small cell lung cancer , 2017, Oncoimmunology.

[32]  Xiaodong Zhang,et al.  The biological function and significance of CD74 in immune diseases , 2017, Inflammation Research.

[33]  Matthias Schröder,et al.  Identification of inhibitors of myeloid-derived suppressor cells activity through phenotypic chemical screening , 2017, Oncoimmunology.

[34]  Jüergen Cox,et al.  The MaxQuant computational platform for mass spectrometry-based shotgun proteomics , 2016, Nature Protocols.

[35]  J. Lee,et al.  The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells , 2016, Oncoimmunology.

[36]  Marco Y. Hein,et al.  The Perseus computational platform for comprehensive analysis of (prote)omics data , 2016, Nature Methods.

[37]  Y. Teng,et al.  Exosomes miR-126a released from MDSC induced by DOX treatment promotes lung metastasis , 2016, Oncogene.

[38]  S. Mocellin,et al.  Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression , 2015, Oncotarget.

[39]  Jie Zhou,et al.  Norepinephrine-induced myeloid-derived suppressor cells block T-cell responses via generation of reactive oxygen species , 2015, Immunopharmacology and immunotoxicology.

[40]  B. Kuster,et al.  Optimized chemical proteomics assay for kinase inhibitor profiling. , 2015, Journal of proteome research.

[41]  Hanspeter Pfister,et al.  UpSet: Visualization of Intersecting Sets , 2014, IEEE Transactions on Visualization and Computer Graphics.

[42]  Marco Y. Hein,et al.  Accurate Proteome-wide Label-free Quantification by Delayed Normalization and Maximal Peptide Ratio Extraction, Termed MaxLFQ * , 2014, Molecular & Cellular Proteomics.

[43]  A. Wilk,et al.  Subpopulations of myeloid‐derived suppressor cells impair T cell responses through independent nitric oxide‐related pathways , 2014, International journal of cancer.

[44]  Edward L. Huttlin,et al.  MultiNotch MS3 Enables Accurate, Sensitive, and Multiplexed Detection of Differential Expression across Cancer Cell Line Proteomes , 2014, Analytical chemistry.

[45]  A. Mahmoud,et al.  Warburg effect increases steady-state ROS condition in cancer cells through decreasing their antioxidant capacities (anticancer effects of 3-bromopyruvate through antagonizing Warburg effect). , 2013, Medical hypotheses.

[46]  Q. Hu,et al.  Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. , 2013, The Journal of clinical investigation.

[47]  Bernhard Kuster,et al.  DMSO enhances electrospray response, boosting sensitivity of proteomic experiments , 2013, Nature Methods.

[48]  P. De Baetselier,et al.  Instruction of myeloid cells by the tumor microenvironment , 2012, Oncoimmunology.

[49]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[50]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[51]  N. L. La Thangue,et al.  HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications , 2012, Immunology and cell biology.

[52]  Jonathan B. Mitchem,et al.  Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer. , 2011, Current cancer drug targets.

[53]  P. Grandi,et al.  Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes , 2011, Nature Biotechnology.

[54]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[55]  B. Rini,et al.  Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. , 2010, Cancer research.

[56]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[57]  D. Foell,et al.  Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells1 , 2008, The Journal of Immunology.

[58]  P. Rodriguez,et al.  Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives , 2008, Immunological reviews.

[59]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[60]  C. Divino,et al.  Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. , 2006, Cancer research.

[61]  V. Bronte,et al.  Regulation of immune responses by L-arginine metabolism , 2005, Nature Reviews Immunology.

[62]  Christine Brun,et al.  In silico prediction of protein-protein interactions in human macrophages , 2001, BMC Research Notes.

[63]  M. Shurin,et al.  Targeting Myeloid-Derived Suppressor Cells in Cancer. , 2017, Advances in experimental medicine and biology.

[64]  D. Gabrilovich,et al.  Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. , 2011, Trends in immunology.

[65]  Fu-Tsai Chung,et al.  Population alterations of l-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14−/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer , 2009, Journal of Cancer Research and Clinical Oncology.

[66]  M. Nishimura,et al.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy , 2008, Cancer Immunology, Immunotherapy.

[67]  M. Colombo,et al.  The terminology issue for myeloid-derived suppressor cells. , 2007, Cancer research.

[68]  Hua Yu,et al.  Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells , 2004, Nature Medicine.